|
CME News
Few Remissions From Switching to Other DMARDs After MTX Failure
If initial MTX fails to produce remission in RA, adding or switching to other conventional DMARDs is also unlikely to produce remissions...
Rheumatology News
Breaking News: FDA Heightens Warning About Miscarriage, Birth Defects With Drug Used Off-Label for Lupus Nephritis
FDA has raised the warning level for mycophenolate mofetil (MMF) from Category C to Category D (positive evidence of fetal risk)...
BioPharm Business News
Lilly Acquires TRPV1 Antagonist Portfolio Including Phase II Drug Candidate GRC 6211 From Glenmark for Treatment of Pain, Including Osteoarthritic Pain
Eli Lilly and Co announced that it has entered into a license agreement with Glenmark Pharmaceuticals SA, a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd, under which Lilly will acquire the rights to a portfolio of transient receptor potential vanilloid subfamily 1 (TRPV1) antagonist molecules, including the clinical compound GRC 6211...
Rheumatology News
Low-Dose Glucocorticoids Halve Risk of Treatment-Limiting Infliximab Infusion Reactions
Treatment-limiting infliximab infusion reactions were significantly less frequent in RA patients who were also taking low-dose glucocorticoids...
BioPharm Business News
Coley Initiates Phase I Study of First-in-Class TLR Antagonist, CPG 52364, for the Treatment of Systemic Lupus Erythematosus
Coley Pharmaceutical Group, Inc, an international biopharmaceutical company having a pipeline of Toll-Like Receptor (TLR) therapeutic product candidates, announced that it has dosed its first subject in a phase I study of its novel, orally-available TLR Therapeutic drug candidate for the treatment of systemic lupus erythematosus (SLE)...
|
